Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENSFree Report) in a report published on Monday morning. The firm issued a sell rating on the stock.

Senseonics Stock Performance

Shares of SENS opened at $0.39 on Monday. The company has a debt-to-equity ratio of 1.79, a current ratio of 3.96 and a quick ratio of 3.70. The stock has a 50-day moving average of $0.44 and a 200-day moving average of $0.53. The company has a market cap of $207.05 million, a PE ratio of -2.79 and a beta of 0.82. Senseonics has a one year low of $0.37 and a one year high of $1.05.

Senseonics (NYSE:SENSGet Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $5.05 million during the quarter, compared to the consensus estimate of $4.76 million. Senseonics had a negative return on equity of 202.32% and a negative net margin of 346.38%. On average, equities research analysts predict that Senseonics will post -0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Senseonics

Several hedge funds have recently modified their holdings of SENS. RPO LLC bought a new position in shares of Senseonics during the 4th quarter worth approximately $37,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares during the period. State Board of Administration of Florida Retirement System bought a new stake in shares of Senseonics in the 1st quarter worth approximately $91,000. Vanguard Group Inc. raised its holdings in shares of Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the period. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

(Get Free Report)

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

Featured Articles

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.